This week, we cover interesting research from TTLC 2024, focusing on innovative treatments for lung cancer. Starting off, Bruna Pellini from Moffitt Cancer Center, FL, talks about the utility of circulating tumor DNA as a biomarker of progression in lung cancer, her latest findings from notable Phase III trials and ongoing studies looking into increasing treatment based on this biomarker.

Next, Monica Chen from Memorial Sloan Kettering Cancer Center, NY, discusses the role of osimertinib with chemotherapy as initial treatment for patients with metastatic EGFR mutant lung cancers with concurrent TP53 and RB1 alterations from a clinical trial perspective.

Our final speaker, Timothy Burns from University of Pittsburgh, PA, shares detailed insights into non-TKI treatment options for EGFR mutant lung cancer. He discusses the exciting prospects of upcoming studies, potential FDA approvals and the integrated role of immuno-modulatory agents in EGFR mutant patients.

Our podcast aims to deliver the latest and most intriguing updates in the field directly to you. Follow us on Twitter at @vjoncology and visit our website for the newest trends.